Sign up
Log in
MARKET
OPK
OPK
Opko Health
NASDAQ
1.420
-0.015
-1.05%
Pre Market: 1.400 -0.02 -1.41% 08:00 07/26 EDT
OPEN
1.420
PREV CLOSE
1.420
HIGH
1.440
LOW
1.390
VOLUME
2
TURNOVER
0
52 WEEK HIGH
2.175
52 WEEK LOW
0.8516
MARKET CAP
989.73M
P/E (TTM)
-4.1436
1D
5D
1M
3M
1Y
5Y
1D
U.S. RESEARCH ROUNDUP-Colgate-Palmolive, McKesson, Microsoft
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Colgate-Palmolive, McKesson, Microsoft and Air Products & Chemicals among those. AIG, AIG and others have seen their target prices cut by some analysts.
Reuters · 3d ago
OPKO HEALTH INC <OPK.O>: JEFFERIES CUTS TARGET PRICE TO $2 FROM $2.5
Reuters · 3d ago
Weekly Report: what happened at OPK last week (0715-0719)?
Weekly Report · 4d ago
BUZZ-U.S. STOCKS ON THE MOVE-Allstate, Quanta, First Industrial Realty
Wall Street's major indexes reversed early gains on Thursday. The Dow Jones Industrial Average was down 0.66% at 40,925.7. The top three S&P 500 percentage gainers were D.R. Horton, Barnes & Noble and First Industrial Realty.
Reuters · 07/18 17:56
BUZZ-U.S. STOCKS ON THE MOVE-Meta Platforms, Cintas, Toast
The Nasdaq and the S&P 500 bounced back on Thursday. An upbeat forecast from Taiwan Semiconductor Manufacturing lifted chip stocks after a sharp sell-off in the previous session. The Dow Jones Industrial Average was down 0.80% and the Nasdaq Composite was also down. Meta Platforms, Cintas and Toast are up.
Reuters · 07/18 16:49
Opko Health Stock Is Climbing: What's Going On?
Opko Health, Inc. Announced a $100 million share repurchase program. The company expects to fund the program from existing cash and cash equivalents and future cash flows. The new authorization represents 10.1% of the company's shares outstanding. Opko Health shares are trading higher Thursday.
Benzinga · 07/18 15:13
Cintas Posts Upbeat Earnings, Joins CommScope Holding, Virtu Financial And Other Big Stocks Moving Higher On Thursday
Shares of Cintas Corporation rose 5.3% to $758.25 after the company reported better-than-expected quarterly results. Dow Jones index gained 150 points on Thursday. Chuy’s Holdings, Inc. Shares gained 47.6% after company announced plans to acquire Chuy's.
Benzinga · 07/18 14:29
BUZZ-Opko Health climbs on stock buyback plan
Opko Health shares up 8.4% premarket to $1.54, highest since beginning of 2024. Biopharma and diagnostics firm plans to buy back stock. Co announces $100 mln share buyback program. Average rating among 6 analysts covering OPK is "strongbuy"
Reuters · 07/18 13:22
About OPK
OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company's diagnostics segment consists of the clinical laboratory operations of BioReference Health, LLC (BioReference), its point-of-care operations. Its pharmaceutical segment consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. Through BioReference, it operates specialized laboratory divisions, such as GenPath (Urology), GenPath (Oncology), and GenPath (Women's Health). It has two commercial stage pharmaceutical products and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Rayaldee, Rayaldee, Oxyntomodulin, Biologics, NGENLA Somatrogon, and Factor VIIa-CTP. It develops and manufactures specialty active pharmaceutical ingredients (APIs) through FineTech Pharmaceutical, Ltd.
Webull offers OPKO Health Inc stock information, including NASDAQ: OPK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OPK stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.
You can practice and explore trading OPK stock methods without spending real money on the virtual paper trading platform.